Vav1 mutations: What makes them oncogenic?

Marganit Farago; Tali Yarnitzky; Batel Shalom; Shulamit Katzav

doi:10.1016/j.cellsig.2019.109438

October 22, 2019Cellular SignallingOpen Access

Vav1 mutations: What makes them oncogenic?

View Full Paper

Ask AI

Bookmark

Share

Key Points

Examine the biochemical and functional mechanisms through which specific Vav1 mutations promote oncogenic transformation in human malignancies.
Synthesized functional and biochemical data characterizing the tumorigenic properties of Vav1 mutants, including E59K, D517E, and L801P.
Evaluated the alignment between computer-predicted structural properties and experimentally tested biochemical phenotypes of mutant Vav1 proteins.
Identified distinct biochemical alterations across Vav1 mutants that contribute directly to oncogenic activity in both hematologic and non-hematologic tissues.
Demonstrated that integrating computational structural modeling with wet-lab experimental findings confirms Vav1 as a bona fide human oncogene.

Implication

Narrative review reveals how specific Vav1 mutations drive tumorigenesis across diverse human malignancies, supporting its classification as a bona fide oncogene.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Farago et al. (2019) studied this question.

synapsesocial.com/papers/6aa46c774ad6d94037dc358c https://doi.org/10.1016/j.cellsig.2019.109438

View Full Paper

Ask AI

Bookmark

Share

Vav1 mutations: What makes them oncogenic?

Key Points

Implication

Abstract

Discussion

Cite This Study

Vav1 mutations: What makes them oncogenic?

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading